A VISIONaerie® approach
We discover, develop and commercializefirst-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases
News Highlights
Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the ... Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 (TRPM8 ... Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and R...STOCK Quote
NASDAQ: AERI
$12.65USD
Dec 3, 4:00 PM ET
VOLUME
309,894
DAY LOW/HIGH
$12.52/$12.90
52 - WEEK LOW/HIGH
$9.01/$26.26
